Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) reached a new 52-week low during trading on Monday . The stock traded as low as $3.80 and last traded at $3.85, with a volume of 4619593 shares trading hands. The stock had previously closed at $4.24.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the stock. KeyCorp dropped their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $8.20.
Read Our Latest Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Up 27.7 %
The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average of $6.83 and a two-hundred day moving average of $6.84. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -3.76 and a beta of 1.00.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company's revenue for the quarter was down 57.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.42) earnings per share. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of RXRX. Green Alpha Advisors LLC grew its position in Recursion Pharmaceuticals by 166.4% during the 1st quarter. Green Alpha Advisors LLC now owns 178,873 shares of the company's stock worth $946,000 after acquiring an additional 111,728 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Recursion Pharmaceuticals by 7.5% during the first quarter. Rhumbline Advisers now owns 359,175 shares of the company's stock worth $1,900,000 after purchasing an additional 25,143 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Recursion Pharmaceuticals by 635.2% in the first quarter. GAMMA Investing LLC now owns 38,215 shares of the company's stock valued at $202,000 after buying an additional 33,017 shares during the period. Wellington Management Group LLP raised its holdings in Recursion Pharmaceuticals by 9.5% in the 4th quarter. Wellington Management Group LLP now owns 114,945 shares of the company's stock valued at $777,000 after buying an additional 9,927 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Recursion Pharmaceuticals by 30.7% during the 4th quarter. California State Teachers Retirement System now owns 231,535 shares of the company's stock worth $1,565,000 after buying an additional 54,449 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
